Year All2024202320222021202020192018201720162015201420132012201120102007 05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23% - - Company on track to initiate pivotal Phase 2 portion of AUGMENT-101 trial in 2Q21 - - Enrollment of 23 cGVHD patients in Phase Read More 05.04.21 Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 WALTHAM, Mass. , May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial Read More 04.20.21 Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias - 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status - - Doses identified for advancement into Phase 2 - - Company on track to initiate pivotal Phase 2 portion of trial in 2Q21- - Company to host conference call and webcast Read More 04.15.21 Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET - WALTHAM, Mass. , April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, Read More 04.08.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis WALTHAM, Mass. , April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More 03.31.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease WALTHAM, Mass. , March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More 03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commence in 2Q21 - - Enrollment underway in pivotal Phase 2 AGAVE-201 trial of axatilimab in cGVHD - - End of year cash balance of $293.1 million provides cash runway into 2023- - Company to host Read More 03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 WALTHAM, Mass. , March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 Read More 02.24.21 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More 12.18.20 Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index WALTHAM, Mass. , Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the Read More 12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass , Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More 12.09.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of Read More
05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23% - - Company on track to initiate pivotal Phase 2 portion of AUGMENT-101 trial in 2Q21 - - Enrollment of 23 cGVHD patients in Phase Read More
05.04.21 Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 WALTHAM, Mass. , May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial Read More
04.20.21 Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias - 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status - - Doses identified for advancement into Phase 2 - - Company on track to initiate pivotal Phase 2 portion of trial in 2Q21- - Company to host conference call and webcast Read More
04.15.21 Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET - WALTHAM, Mass. , April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, Read More
04.08.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis WALTHAM, Mass. , April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More
03.31.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease WALTHAM, Mass. , March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More
03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commence in 2Q21 - - Enrollment underway in pivotal Phase 2 AGAVE-201 trial of axatilimab in cGVHD - - End of year cash balance of $293.1 million provides cash runway into 2023- - Company to host Read More
03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 WALTHAM, Mass. , March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 Read More
02.24.21 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More
12.18.20 Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index WALTHAM, Mass. , Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the Read More
12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass , Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More
12.09.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of Read More